<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25743">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771626</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-004</org_study_id>
    <nct_id>NCT02771626</nct_id>
  </id_info>
  <brief_title>Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma and Other Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in
      patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in
      patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

      During Phase 1, patients will be enrolled into escalating dose cohorts to determine the
      recommended phase 2 dose (RP2D).

      In Phase 2, patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung
      cancer will be enrolled into separate cohorts.

      All patients will be assessed for safety, pharmacokinetics, biomarkers and tumor response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of CB-839 and Nivolumab: Incidence of adverse events</measure>
    <time_frame>Every 28 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of CB-839 in Combination with Nivolumab: change in tumor size from baseline</measure>
    <time_frame>Every 28 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) of CB-839 in Combination with Nivolumab</measure>
    <time_frame>12 Weeks</time_frame>
    <description>A minimum of 9-12 patients with ccRCC, melanoma, or NSCLC will be enrolled in Dose Escalation to determine RP2D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of CB-839 in combination with Nivolumab</measure>
    <time_frame>Every 28 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
    <description>Non-compartmental method of analysis will be used to analyze the plasma concentrations of CB-839.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CB-839 + Nivolumab Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: CB-839 administered as oral capsules twice daily in combination with standard dose nivolumab in patients with advanced/metastatic ccRCC, MEL, and NSCLC to select the recommended Phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clear Cell RCC Naïve to Checkpoint Inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC who have previously received at least one TKI but are treatment naive to checkpoint modulators anti-PD-1/PD-L1, CTLA-4, or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clear Cell RCC Recently Treated with Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC who received nivolumab in most treatment line that had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clear Cell RCC with Prior PD-1 Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 - Cohort 3: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/ PD-L1 therapy in any prior line of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melanoma with Prior PD-1 Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4: CB-839/ nivolumab combination in patients with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC with Prior PD-1 Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5: CB-839/ nivolumab combination with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and have received an anti-PD-1 monotherapy in their most recent line of therapy with minimal washout (&lt; 8 weeks), with the intent of adding CB-839 to an ongoing anti-PD-1 regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-839</intervention_name>
    <description>Glutaminase inhibitor</description>
    <arm_group_label>CB-839 + Nivolumab Dose Escalation</arm_group_label>
    <arm_group_label>Clear Cell RCC Naïve to Checkpoint Inhibitors</arm_group_label>
    <arm_group_label>Clear Cell RCC Recently Treated with Nivolumab</arm_group_label>
    <arm_group_label>Clear Cell RCC with Prior PD-1 Therapy</arm_group_label>
    <arm_group_label>Melanoma with Prior PD-1 Therapy</arm_group_label>
    <arm_group_label>NSCLC with Prior PD-1 Therapy</arm_group_label>
    <other_name>Glutaminase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>PD-1 inhibitor</description>
    <arm_group_label>CB-839 + Nivolumab Dose Escalation</arm_group_label>
    <arm_group_label>Clear Cell RCC Naïve to Checkpoint Inhibitors</arm_group_label>
    <arm_group_label>Clear Cell RCC Recently Treated with Nivolumab</arm_group_label>
    <arm_group_label>Clear Cell RCC with Prior PD-1 Therapy</arm_group_label>
    <arm_group_label>Melanoma with Prior PD-1 Therapy</arm_group_label>
    <arm_group_label>NSCLC with Prior PD-1 Therapy</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Addition eligibility criteria based on tumor type apply

        Inclusion Criteria:

          -  Ability to provide written informed consent in accordance with federal, local, and
             institutional guidelines

          -  Histological or cytological diagnosis of metastatic cancer or locally advanced cancer
             that is not amenable to local therapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          -  Life Expectancy of at least 3 months

          -  Adequate hepatic, renal, cardiac, and hematologic function

          -  Measurable disease by RECISTv1.1 criteria

          -  Resolution of treatment-related toxicities except alopecia

        Exclusion Criteria:

          -  Unable to receive oral medications

          -  Unable to receive oral or IV hydration

          -  Intolerance to prior anti-PD-1/PD-L1 therapy

          -  Prior severe hypersensitivity reaction to another monoclonal antibody (mAb)

          -  Any other current or previous malignancy within 3 years except protocol allowed
             malignancies

          -  Chemotherapy, Tyrosine Kinase Inhibitor therapy, radiation therapy or hormonal
             therapy within 2 weeks

          -  Immunotherapy or biological therapy, or investigational agent within 3 weeks (Note:
             Some cohort exceptions allow anti-PD-1 therapy)

          -  Active known or suspected exclusionary autoimmune disease

          -  Any condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily
             prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks

          -  History of known risks factors for bowel perforation

          -  Symptomatic ascites or pleural effusion

          -  Major surgery within 28 days before Cycle 1 Day 1

          -  Active infection requiring within 2 weeks prior to first dose of study drug

          -  Patients who have HIV, Hepatitis B or C

          -  Conditions that could interfere with treatment or protocol-related procedures

          -  Active, non-stable brain metastases or CNS disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Whiting, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elaine Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Bonston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David McDermott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>855-320-2090</phone>
    </contact>
    <investigator>
      <last_name>Rana McKay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Caner Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulka Vaishampayan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Voss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Funda Meric-Bernstam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Tykodi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jorge Chaves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 19, 2017</lastchanged_date>
  <firstreceived_date>May 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RCC</keyword>
  <keyword>MEL</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Immuno-Oncology</keyword>
  <keyword>Tumor Metabolism</keyword>
  <keyword>Glutaminase</keyword>
  <keyword>Glutaminase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
